University of Campania Luigi Vanvitelli

unicampania.it

Total trials

171

Active

24

Phase 3

7

Total enrollment

59,075

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 9 of 9 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Insulin injections1
FOLFIRI2
Bevacizumab2
Erbitux1
FOLFOX1
Cetuximab3
FOLFOX regimen1
Irinotecan1
umPEALUT + Rutin + 5 hTp1

Next readouts

  • 2026-08-15
  • 2026-10-31
  • 2026-12
  • 2030-10

Top conditions

  • Heart Failure8
  • Atrial Fibrillation5
  • Type 2 Diabetes Mellitus4
  • Diabetes Mellitus4
  • Obesity4
  • Type 2 Diabetes4
  • Diabetes Mellitus, Type 23
  • Endometrial Neoplasms3

Frequently asked questions about University of Campania Luigi Vanvitelli

How many clinical trials does University of Campania Luigi Vanvitelli have on ClinicalTrials.gov?
University of Campania Luigi Vanvitelli is listed as the lead sponsor on 171 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Campania Luigi Vanvitelli's trials are in Phase 3?
7 of University of Campania Luigi Vanvitelli's trials are in Phase 3, spread across 9 active drug programs.
What therapeutic areas does University of Campania Luigi Vanvitelli focus on?
University of Campania Luigi Vanvitelli's most-studied conditions on ClinicalTrials.gov are Heart Failure, Atrial Fibrillation, Type 2 Diabetes Mellitus, Diabetes Mellitus, Obesity.
When are University of Campania Luigi Vanvitelli's next clinical trial readouts?
University of Campania Luigi Vanvitelli has 4 upcoming primary-completion readouts tracked here; the soonest is “CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen”, expected around 2026-08-15.